Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
EditorialEditorial

Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells

ANNE TOURNADRE and PIERRE MIOSSEC
The Journal of Rheumatology February 2013, 40 (2) 110-112; DOI: https://doi.org/10.3899/jrheum.121315
ANNE TOURNADRE
Department of Rheumatology, CHU Clermont-Ferrand, Clermont-Ferrand;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: atournadre@chu-clermontferrand.fr
PIERRE MIOSSEC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Idiopathic inflammatory myopathies (IIM) are a group of chronic muscle disorders of unknown origin that lead to muscle destruction. The original classification of IIM proposed by Bohan and Peter in 1975 including polymyositis (PM) and dermatomyositis (DM) was recently revised with the development of histopathological approaches and the discovery of myositis-specific and myositis-associated antibodies that led to the characterization of new entities. In addition to PM and adult and juvenile DM, these novel classifications distinguish inclusion-body myositis (IBM), immune-mediated necrotizing myopathy, overlap myositis, and cancer-associated myositis1,2. While distinct immunopathogenic mechanisms may occur in each subset of myositis, all IIM share a common inflammatory background associated with clinical, histological, and serological overlap. Several molecular pathways, such as adaptive and innate immune responses, autoimmunity, and nonimmune mechanisms, could influence the pathogenesis of IIM. However, the exact contribution of each one in the development of distinct phenotypes remains unclear. In this issue of The Journal, Gendek-Kubiak and Gendek highlight the contribution of dendritic cells (DC)3. We summarize here recent insights in myositis immunoregulation from DC that are central in the development of adaptive and innate response to nonimmune mechanisms.

Dendritic cells

DC are crucial for the development of adaptive and innate immune responses. DC, subdivided into myeloid DC (mDC) and plasmacytoid DC (pDC), are present in lymphatic and blood systems and peripheral organs. They are equipped with a range of pattern-recognition receptors (PRR) and serve as sentinels of the immune system. Their activation after stimulation of PRR, such as Toll-like receptors (TLR) or C-type lectin receptors (CLR), by microbial components and/or endogenous ligands leads to their maturation and the development of an effector T cell immune response. In muscle biopsies from IIM, both myeloid and plasmacytoid DC have been detected with differences according to IIM subtypes. The DC present in PM and IBM muscle are mostly mDC, in contrast to adult and juvenile DM, which had greater numbers of pDC expressing CD44,5. The presence of pDC in muscle was also increased in overlap myositis associated with anti-Jo1 or anti-SSA autoantibodies6. An accumulation of mature DC in muscle tissue from IIM is reported in many studies7,8, such as the study by Gendek-Kubiak and Gendek3. In their study, the authors used newly defined markers of immature and mature DC. Langerin/CD207, as CD1a previously used for the identification of immature DC7, is a marker of epidermal and epithelial Langerhans cells. Langerin is a CLR always associated with CD1a expression, and should also be useful for the identification of immature DC. Fascin is a DC protein upregulated during DC maturation that is additionally critical for antigen-presenting cell activity.

Consistent with previous studies, Gendek-Kubiak and Gendek3 found that immature langerin DC were rarely detected compared to fascin-positive mature DC detected in all DM biopsies and in 4 out of 5 PM biopsies, without differences for the localization or the quantification of fascin-expressing DC between PM and DM. Gendek-Kubiak and Gendek3 confirm a common profile of DC subsets between PM and DM, except for a relative accumulation of more mature DC in PM than in DM7. Moreover, the presence in inflamed muscle of DC expressing fascin that is directly involved in the ability of DC to activate T cells, as well as in DC mobility and migration, highlights their local contribution in antigen presentation and T cell activation. Migration of DC is closely regulated during maturation through changes in chemokine receptor expression. The quasi-absence of immature DC reported by Gendek-Kubiak and Gendek3 could suggest an extramuscular maturation of DC in secondary lymphoid organs and a direct migration into muscle. However, the lack of the β chemokines CCL19/CCL21 involved in the migration of mature DC and the presence of CCL20 and its associated receptor CCR6 involved in the migration of immature DC, in association with the expression of immature CD1a-positive DC, suggest a local muscular maturation of DC7. A very similar conclusion was reached in the context of rheumatoid arthritis synovium, with differences compared to normal lymph node organization9. Such DC maturation could be enhanced by the presence in the microenvironment of proinflammatory cytokines such as interleukin 1 (IL-1) and tumor necrosis factor-α (TNF-α)10. Finally, the nature of PRR expressed by DC, the type of PRR ligand, and the micro-environment in which DC are located determine the behavior of DC and the orientation of the immune response. Myeloid DC are potent antigen-presenting cells of adaptive immunity that stimulate T and B lymphocytes capable of highly specific response-promoting distinct phenotypes of Th cells. Plasmacytoid DC support innate immunity, in particular against viral infection, through the production of type I interferon (IFN).

T cell immunity

IIM are characterized by the presence in muscle tissue of lymphocytic infiltrates consisting of CD8+ and CD4+ T cells. In PM and IBM, endomysial CD8+ T cells surround and invade muscle fibers expressing MHC class I antigens. DM is characterized by a perivascular inflammation with CD4+ T cells, associated with capillary modifications that lead to perifascicular atrophy. The autoimmune origin of IIM is supported by a T cell-mediated myocytotoxicity and by observation of clonally expanded autoinvasive T cells in blood and muscle of PM11,12. Multiple and complex variables contribute to the development of naive CD4+ T cells into Th1, Th2, Th17, or Treg cells. Many studies suggest a main Th1 profile in IIM. In muscle tissue from both PM and DM, the Th1 cytokine interferon-γ (IFN-γ) is largely detected7,8,10, as well as IL-1213 and IL-1814 produced by activated DC and involved in Th1 polarization. In addition to the Th1 pathway, the presence in lymphocytic infiltrates of myositis muscle of IL-17-producing cells, as well as IL-23 produced by activated DC and involved in Th17 polarization, suggests a contribution of the IL-23-Th17 pathway7,8,13. IL-17 can act together with other proinflammatory cytokines to amplify and maintain the immune response that leads to muscle destruction15. IL-17 acts in synergy with IL-1 and TNF-α to induce the production by muscle cells and mononuclear cells of IL-6 and of the β chemokine CCL20, which in turn contribute to the differentiation and recruitment of Th17 and immature DC.

B cell and humoral immunity

Humoral immunity is mediated through antibody-producing plasma cells after maturation of B cells following presentation of autoantigens to activated CD4+ Th cells. The autoimmune origin of IIM is supported by the presence of specific or associated myositis autoantibodies/autoantigens. Besides their use for diagnosis and classification, they also contribute to the initiation and maintenance of the immune response. In PM, DM, and immune-mediated necrotizing myopathy, myositis-specific autoantigens such as histidyl-tRNA synthetase, Mi-2, and HMG-CoA reductase are over expressed in immature regenerating muscle cells also expressing high levels of HLA class I antigens16,17. Chemoattractive properties of autoantigenic aminoacyl-tRNA synthetases contribute to the migration and recruitment of T cells and DC. Moreover, myositis autoantibodies may act in combination with immune complexes and necrotic cells as endogenous IFN-α inducers6.

Innate immunity

Studies identified the contribution of the innate immune system through activation of the type I IFN system and TLR pathway in addition to the adaptive immune response6,13,18. Type I IFN-induced genes and proteins are upregulated in blood and muscle from PM and DM6,19. However, the exact source of type I IFN remains unclear because pDC, a major source of type I IFN, are rare and scattered in myositis muscle. Regenerating immature muscle fibers were identified as a local possible source of IFN-ß after activation of the TLR3 pathway and in the context of a Th1 microenvironment13. In turn, such production of type I IFN could favor HLA class I upregulation on muscle cells. Activation by endogenous ligands and self-antigens of TLR associated with nucleic acid-based pathogen-associated molecular pattern recognition may contribute to autoimmunity. In PM and DM, overexpression of TLR3 and TLR7, specifically in immature muscle fibers, has been demonstrated18. Moreover, activation of TLR3 pathways by necrotic cells, in synergy with IL-17, induces in vitro the production by muscle cells of IL-6 and CCL20, which are involved in Th17 differentiation and migration18. In addition to TLR, CLR have been detected in inflamed muscle from PM and DM, in association with mDC, IL-12, and IL-23 cytokines13. Those CLR-expressing cells were preferentially located around immature regenerating muscle fibers, expressing high levels of HLA class I antigens, suggesting that these muscle cells could represent a target of the immune response13.

Nonimmune mechanisms

Damaged muscle tissue caused by IIM is characterized by a degenerating process combined with muscle regeneration. However, it is unclear whether this regeneration is effective in the context of inflammation. Of note, in IIM, immature muscle fibers in charge of regeneration are characterized by the overexpression of myositis-specific autoantigens, HLA class I antigens, TLR3/7, and type I IFN13,16,18. Upregulation of HLA class I antigens on muscle fibers is a key characteristic of myositis muscle tissue. In addition to the immunological role of HLA class I molecules in the presentation of antigens, HLA class I overexpression on muscle cells may mediate muscle damage and dysfunction by itself through activation of the endoplasmic reticulum stress response pathway20. Then, the release of myositis autoantigens from damaged immature muscle cells may activate the type I IFN system when combined with necrotic cell material6, and activation of the TLR3 pathway may amplify the production of IFN-β that in turn could contribute to HLA class I upregulation on muscle cells13,18. Focusing on these regenerating muscle fibers associated with this particular phenotype allows the formation of a self-sustaining inflammatory loop that leads to muscle wasting and defective regeneration.

REFERENCES

  1. 1.↵
    1. Hoogendijk JE,
    2. Amato AA,
    3. Lecky BR,
    4. Choy EH,
    5. Lundberg IE,
    6. Rose MR,
    7. et al.
    119th ENMC International Workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion-body myositis. Neuromuscul Disord 2004;14:337–45.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Troyanov Y,
    2. Targoff IN,
    3. Tremblay JL,
    4. Goulet JR,
    5. Raymond Y,
    6. Senecal JL
    . Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies. Analysis of 100 French Canadian patients. Medicine 2005;84: 231–49.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Gendek-Kubiak H,
    2. Gendek EG
    . Fascin-expressing dendritic cells dominate in polymyositis and dermatomyositis. J Rheumatol 2012;40:186.
    OpenUrl
  4. 4.↵
    1. Greenberg SA,
    2. Pinkus GS,
    3. Amato AA,
    4. Pinkus JL
    . Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35:17–23.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Lopez de Padilla CM,
    2. Vallejo AN,
    3. McNallan KT,
    4. Vehe R,
    5. Smith SA,
    6. Dietz AB,
    7. et al.
    Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007;56:1658–68.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Eloranta ML,
    2. Barbasso Helmers S,
    3. Ulfgren AK,
    4. Rönnblom L,
    5. Alm GV,
    6. Lundberg IE
    . A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112–24.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Page G,
    2. Chevrel G,
    3. Miossec P
    . Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cell. Arthritis Rheum 2004;50:199–208.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Tournadre A,
    2. Porcherot M,
    3. Chérin P,
    4. Marie I,
    5. Hachulla E,
    6. Miossec P
    . Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009;46:297–301.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Page G,
    2. Lebecque S,
    3. Miossec P
    . Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002;168:5333–41.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Tournadre A,
    2. Miossec P
    . Cytokine response in inflammatory myopathies. Curr Rheumatol Rep 2007;9:286–90.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hohlfeld R,
    2. Engel AG
    . Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991;29:498–507.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Benveniste O,
    2. Chérin P,
    3. Maisonobe T,
    4. Merat R,
    5. Chosidow O,
    6. Mouthon L,
    7. et al.
    Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001;167:3521–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Tournadre A,
    2. Lenief V,
    3. Eljaafari A,
    4. Miossec P
    . Immature muscle precursors are a source of interferon-beta in myositis: Role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2012;64:533–41.
    OpenUrlPubMed
  14. 14.↵
    1. Tucci M,
    2. Quatraro C,
    3. Dammacco F,
    4. Silvestris F
    . Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21–31.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Tournadre A,
    2. Miossec P
    . Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 2012;14:252–6.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Casciola-Rosen L,
    2. Nagaraju K,
    3. Plotz P,
    4. Wang K,
    5. Levine S,
    6. Gabrielson E,
    7. et al.
    Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201:591–601.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Mammen AL,
    2. Chung T,
    3. Christopher-Stine L,
    4. Rosen P,
    5. Rosen A,
    6. Doering KR,
    7. et al.
    Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713–21.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Tournadre A,
    2. Lenief V,
    3. Miossec P
    . Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010;62:2144–51.
    OpenUrlPubMed
  19. 19.↵
    1. Walsh RJ,
    2. Kong SW,
    3. Yao Y,
    4. Jallal B,
    5. Kiener PA,
    6. Pinkus JL,
    7. et al.
    Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784–92.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Nagaraju K,
    2. Casciola-Rosen L,
    3. Lundberg I,
    4. Rawat R,
    5. Cutting S,
    6. Thapliyal R,
    7. et al.
    Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824–35.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 2
1 Feb 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells
ANNE TOURNADRE, PIERRE MIOSSEC
The Journal of Rheumatology Feb 2013, 40 (2) 110-112; DOI: 10.3899/jrheum.121315

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells
ANNE TOURNADRE, PIERRE MIOSSEC
The Journal of Rheumatology Feb 2013, 40 (2) 110-112; DOI: 10.3899/jrheum.121315
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Transfer from Pediatric to Adult Care Is Hardly Child’s Play
  • Real-world Evidence Needs Careful Interpretation
  • Relapsing Polychondritis and Large-vessel Vasculitis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire